Page last updated: 2024-09-03

11-hydroxy-n-(n-propyl)noraporphine and Parkinson Disease

11-hydroxy-n-(n-propyl)noraporphine has been researched along with Parkinson Disease in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gao, B; Guo, L; Liu, Z; Ye, N; Zhang, A; Zhang, H; Zhen, X; Zheng, L; Zhou, S1

Other Studies

1 other study(ies) available for 11-hydroxy-n-(n-propyl)noraporphine and Parkinson Disease

ArticleYear
Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile.
    Journal of medicinal chemistry, 2011, Jul-14, Volume: 54, Issue:13

    Topics: Animals; Antiparkinson Agents; Aporphines; Binding, Competitive; CHO Cells; Corpus Striatum; Cricetinae; Cricetulus; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Levodopa; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Radioligand Assay; Rats; Receptors, Adrenergic; Receptors, Dopamine D2; Serotonin 5-HT1 Receptor Agonists; Stereoisomerism; Structure-Activity Relationship; Thioctic Acid

2011